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Abstract
Background: Our laboratory has shown that a locus on the SHR Y chromosome increases blood
pressure (BP) in the SHR rat and in WKY rats that had the SHR Y chromosome locus crossed into
their genome (SHR/y rat). A potential candidate for this Y chromosome hypertension locus is Sry,
a gene that encodes a transcription factor that is responsible for testes development and the Sry
protein may affect other target genes.
Methods: The following study examined if exogenous Sry would elevate adrenal Th, adrenal
catecholamines, plasma catecholamines and blood pressure. We delivered 10 μg of either the
expression construct, Sry1/pcDNA 3.1, or control vector into the adrenal medulla of WKY rats by
electroporation. Blood pressure was measured by the tail cuff technique and Th and
catecholamines by HPLC with electrochemical detection.
Results: In the animals receiving Sry there were significant increases after 3 weeks in resting
plasma NE (57%) and adrenal Th content (49%) compared to vector controls. BP was 30 mmHg
higher in Sry injected animals (160 mmHg, p < .05) compared to vector controls (130 mmHg) after
2–3 weeks. Histological analysis showed that the electroporation procedure did not produce
morphological damage.
Conclusion:  These results provide continued support that Sry is a candidate gene for
hypertension. Also, these results are consistent with a role for Sry in increasing BP by directly or
indirectly activating sympathetic nervous system activity.
Background
We have shown previously that there is a locus on the SHR
Y chromosome that increases blood pressure (BP) about
20–25 mmHg [1,2]. Backcrosses of the SHR Y chromo-
some into WKY rats show a significant Y chromosome BP
increase of 20 mmHg [3]. Further studies showed that the
SHR Y chromosome increased several indices of SNS activ-
ity [4]. We demonstrated that renal norepinephrine (NE)
turnover rate is higher by 100% [5] and renal NE content
is 44% higher in males with the Y chromosome from an
SHR [5]. Our recent studies indicate that a candidate gene
for this SNS and BP effect is Sry, a transcription factor on
the Y chromosome that is the testis determining factor [6].
Sry expression has been reported in testis, the brain and in
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additional tissues that have BP relevance in adult humans
and rodents [7-9]. Recently, we demonstrated that Sry
increased tyrosine hydroxylase (Th) promoter activity in
transfected PC12 cells [6] although much of the effect was
indirect. Th catalyzes the conversion of L-tyrosine to L-
dihydroxyphenylalanine (L-DOPA) which ultimately
leads to the formation of dopamine and NE. Th is the rate
limiting enzyme in the catecholamine biosynthesis path-
way; thus regulation of Th by Sry is a potential pathway
for Sry to affect BP. Since the effect of Sry in adult males is
not understood there may be a variety of mechanisms
raising BP by Sry.
Based on these findings we developed the following
hypothesis: delivery of exogenous Sry to the adrenal
medulla of a WKY rat increases Th activity in the adrenal
medulla, thereby leading to elevated plasma NE and
increased BP. To address this hypothesis, we added exog-
enous SHR Sry gene sequences to the adrenal medulla of
a normotensive WKY rat using gene delivery by electropo-
ration to see if there was an increase in Th, NE and BP.
While the electroporation technique of gene delivery was
developed for use primarily in cell culture, it has also been
successfully used in various tissues in the whole animal.
Procedures using DNA injection coupled with electros-
timulation increased efficiency over both direct injection
into skeletal muscle (by 100×–1000×) [10] and in the use
of adenoviral techniques for gene delivery to gliomas
(100× increase) [11]. In other studies, delivery of exoge-
nous genes produced physiological responses in nephrec-
tomized rats, where rat erythropoietin injection corrected
anemia [12], and in another study raised the hematocrit
from 47% to 80% [13]. Tsuji et al examined the efficiency
of intrarenal injection of DNA followed by in vivo electro-
poration and found that mesangial cells were transfected
and no histological damage was observed [14]. So the lit-
erature supports the notion that delivery of exogenous
DNA can cause physiological changes. Following electro-
poration of Sry into the adrenal medulla of WKY rats, we
show that blood pressure and sympathetic nervous system
indices increase.
Methods
Adult WKY males were used for all studies (n = 24). All
animal protocols were approved by the Institutional Ani-
mal Care and Use Committee of the University of Akron
(IACUC proposal # 03–03A). The experimental design
consisted of two studies. The first study involved the addi-
tion of exogenous Sry or control vector to the adrenal
medulla of normotensive WKY rats. An Sry1 expression
construct, Sry1/pcDNA3.1(-), was prepared by cloning bp
#1–1048 of SHR Sry1 (GenBank accession number
AF274872) of pcDNA3.1(-) (Invitrogen) as described pre-
viously [6]. This includes the complete SHR Sry1 coding
sequence (bp#11–520 of GenBank accession number,
AF274872). Either 10 μg of Sry1/pcDNA3.1(-) (n = 6) or
10  μg of control pcDNA3.1(-) vector without Sry1
sequences (n = 6) was injected into the left adrenal
medulla of 6 WKY adult male rats using pentothal as an
anesthetic (50 mg/kg,ip). Sry or empty vector control was
transfected by injection (Hamilton 10 μL syringe with 30
g needle) followed by electroporation into the adrenal
medulla. A mark was placed on the needle to insure
proper depth to the medulla. A drop of glycerol was
placed on the injection site before injection to prevent
backflow.
In a second study, in order to verify that the electropora-
tion procedure did not cause adrenal damage, the histol-
ogy of the adrenal gland was examined after
electroporation. After stimulation the incision was closed
and the animal allowed to recover. The electroporation
protocol was followed and adult male WKY were injected
with Sry1/pcDNA3.1(-) (n = 6) or empty vector (n = 6)
and electroporated in order to examine the tissue for dam-
age. A control group of WKY adrenal glands (n = 6) that
was not injected or electroporated was also examined.
Electroporation
Each tissue has different optimal electroporation parame-
ters that have been described for gene delivery [11]. Based
on previous research and our own pilot tests we per-
formed electroporation in a pulsatile fashion immediately
after injection. Tweezer electrodes (BTX Tweezertrodes
Model #522) connected to an electrostimulator (Electro-
CellManipulator™, ECM® 830 ELECTROPORATION PRO-
TOCOL, BTX, a division of Genentronics), were placed on
opposite sides of the adrenal gland and 20 bipolar electri-
cal pulses administered, 200 volts, each lasting 20 msec,
at 1000 Hz. After stimulation the incision was closed and
the animal allowed to recover.
Blood Pressure
Systolic blood pressure was measured in conscious ani-
mals by the tail cuff technique weekly for 3 weeks
[1,3,15]. Briefly, the animals are warmed in a heating
chamber (37°C) for 20–30 minutes to vasodilate and 5
consecutive pressures are recorded which takes less than 3
minutes.
Catecholamine Analysis
Levels of adrenal Th and catecholamines, as well as
plasma catecholamines, were measured 3 weeks after elec-
troporation. Th and catecholamines were measured by
HPLC with electrochemical detection (Waters 2465, Mil-
ford, MA). For catecholamines the mobile phase consisted
of citric acid (35 mM), sodium acetate (90 mM), octyl
sodium sulfate (690 μM), EDTA (130 μM) and 10%
methanol, pH adjusted to 4.7. For L-Dopa analysis the
same amount as above were used for the mobile phaseBMC Cardiovascular Disorders 2007, 7:6 http://www.biomedcentral.com/1471-2261/7/6
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except octyl sodium sulfate was increased to 920 μM and
no methanol was added. This was due to the rapid release
of L-Dopa from the column. The pump (Waters 1515) ran
at 1.4 ml/min, 50 ul was injected onto the column
(Waters column, 4.6 × 150 mm, C18, 5 μ, preceded by a
guard column (LC-18, Supelco, Bellfonte, PA). The sam-
ples were maintained at 10°C using the 717 plus
autosampler (Waters, Milford, MA). Catecholamines were
extracted from plasma by placing 300 μl of plasma into 1
ml of 1 M Tris buffer, pH 8.7 (consisting of 1 M Tris,10
mM sodium metabisulfite, 20 mM EDTA (Sigma) with 25
mg of LC-alumina A (Supelco, Bellfonte, PA) and vigor-
ously vortexing for 10 minutes. The samples were then
washed 3× with 1 ml of wash solution (0.2% TRIS-EDTA,
Sigma) and mixed 3 minutes followed by aspiration of the
supernatant after each wash. The last step was the addition
of 400 μl of 100 mM perchloric acid and vortexing for 5
minutes and removal of the supernatant for injection into
the HPLC. The Th activity was calculated by measuring L-
DOPA formed per milligram tissue per minute. Adrenal
glands were homogenized in 500 μl of 0.25 M sucrose.
The homogenate (100 μl) was added to both a blank tube
and a reaction tube. The chemical reaction was based on
procedures developed by Nagatsu [16] and modified by
Hooper et al [17] and Kumai et al. [18] followed by extrac-
tion using the same method as for catecholamines.
Adrenal Gland Morphology
In the second study the adrenal glands were removed,
stored in 10% buffered formalin, dehydrated in a tissue
processor (Tissue-Tek, Miles Inc., Elkhart, IN) and paraffin
embedded (Paraplast Plus, Fisher Sci). Sections were cut at
6 μ and stained with hemotoxylin and eosin (Richard
Allan scientific) to assess the tissue for potential gene
delivery-electroporation injury.
BP and catecholamine levels were analyzed using Stu-
dent's t-tests; means and standard error of the means are
reported; significance was assumed if p < .05.
Results
Figure 1 shows the weekly systolic blood pressure (SBP)
before and during the 3 weeks after delivery of either Sry
or the empty control vector to the adrenal medulla. There
was a significant increase in BP 2–3 weeks after Sry deliv-
ery as compared to control vector, 160 mmHg and 160
mmHg vs. 140 mmHg and 130 mmHg, respectively (p <
.05). Figure 2 shows that 3 weeks after Sry delivery to the
adrenal medulla, Th was significantly increased compared
to the vector control (37,494 vs. 25,181 fmol/min/mg, p
= .017). these values were comparable to Kumai's values
in male WKY (16,670 fmol/mg/min converted to the
units we used) [19]. Figure 3 shows that 3 weeks after Sry
delivery, plasma NE was significantly increased compared
to the vector control group (584 vs. 372 pg/ml, p =.026);
however, there was no change in plasma epinephrine level
between the two groups. With regard to adrenal catecho-
lamine content there were no significant differences
between vector control or Sry groups after 3 weeks
(NE:241+/-102 vs. 247+/-33 ng/mg, E: 1090+/-404 vs.
1220+/-128 ng/mg, respectively). Also the plasma NE val-
ues of the two electroporated groups was similar to previ-
ous values in WKY reported from our lab suggesting that
the electroporation procedure did not damage the adrenal
medulla[20].
Histological examination of the adrenal medulla did not
show any morphological differences between vector con-
trol, Sry delivered or controls without any procedure (Fig-
ure 4). There was concern that electroporation may
damage medullary cells but the morphology of the two
electroporated groups were similar to the non-elctropo-
rated controls.
Discussion
Our main finding is the potential role for Sry in elevating
BP. The time scale of the BP response is consistent with
the responses of other genes delivered by electroporation
which is about 3 weeks for peak effect [21]. The lack of BP
increase with plasmid control vector demonstrates that
the BP increase was due specifically to the addition of Sry
sequences, not to electroporation itself or an effect of the
plasmid sequences.
Adding exogenous Sry DNA from SHR to the adrenal
gland of WKY rats increased BP by 30 mmHg, comparable
to the 20 mmHg effect we see when the SHR Y chromo-
some is added by genetic crosses in our Y chromosome
consomic strains. Typical effects on BP attributed to other
candidate genes or loci are small or equal to the 30 mmHg
effect we find after SHR Sry delivery to WKY adrenal gland.
For instance, in an review of genetic hypertension in rats,
Rapp shows with linkage analysis that in the Dahl salt sen-
sitive rat there are QTLs on chromosome 9 that are associ-
ated with blood pressure increases of 5, 8, 12, 13, 18, 21
and 26 mmHg [22]. However, these are large regions with
many genes that may or may not have physiological func-
tions that influence blood pressure.
The identification of a Y chromosome effect on blood
pressure from a cross between SHR and WKY was the
equivalent to finding a QTL on an autosomal chromo-
some. In this case though, the QTL included all of the
genes on the Y chromosome except those in the pseudo-
autosomal region. A major difference from an autosomal
QTL is the inability to decrease the size of the Y chromo-
some region using crossing over. Because the mammalian
Y chromosome contains very few genes considering its
size, we were able to eliminate most of the Y chromosome
genes from consideration. The Sry locus was first identi-BMC Cardiovascular Disorders 2007, 7:6 http://www.biomedcentral.com/1471-2261/7/6
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fied as a logical candidate because of its potential to mod-
ulate the sympathetic nervous system (SNS) since the
related Sox loci are responsible for nervous system devel-
opment. Following this line of reasoning we have shown
that normotensive WKY animals that have a Y chromo-
some from a SHR father had elevated SNS indices [4,5].
Also we have sympathectomized neonatal males with the
SHR Y chromosme loci and eliminated the rise in BP [23].
We evaluated potential effects of Sry on the tyrosine
hydroxylase promoter. In vitro studies co-transfecting an
Sry expression vector and a tyrosine hydroxylase promoter
controlled reporter gene, confirmed that Sry directly or
indirectly increased tyrosine hydroxylase promoter activ-
ity [6]. Although this demonstrated that Sry has an effect
on the tyrosine hydroxylase promoter in cultured cells,
that doesn't mean that in animals it would necessarily
affect blood pressure. In the current experiments, we have
continued with Sry as a candidate gene but have moved
from cell culture to animal experiments.
We provide evidence here that part of the BP rise may be
due to Th in the adrenal medulla. This does not exclude
other potential targets of Sry, such as, the renin-angi-
otensin system (RAS) and testosterone. We cannot elimi-
nate the RAS as a player in the Sry story so further
investigation is needed. However, we did examine plasma
renin levels after Sry delivery to the kidney in WKY males
and there was no plasma rennin activity difference from
vector controls (unpublished data). With regards to the
possibility that the adrenal cortex may have been involved
due to the medullary injections we have not directly stud-
ied potential steroid targets of Sry, such as, adrenal aldos-
terone, glucocorticoids and testosterone. However, we
have examined renal function and found normal sodium
excretion and creatinine and albumin clearance (unpub-
lished data). One would expect to see altered sodium
excretion if Sry modulated plasma aldosterone levels.
Although an indirect measure of a glucocorticoid effect,
we have measured plasma and urinary glucose after Sry
Systolic blood pressure (SBP) in the vector controls vs Sry injected at baseline weekly for 3 weeks (means, =/-s.e.m., * = p <  .05) Figure 1
Systolic blood pressure (SBP) in the vector controls vs Sry injected at baseline weekly for 3 weeks (means, =/-s.e.m., * = p < 
.05).
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delivery to the kidney and found no effect compared to
controls. We have evidence that plasma corticosterone in
WKY controls was not different than that in WKY males
with the SHR Y chromosome [24]. This suggests that the
SHR Y locus does not endogenously alter corticosterone,
however, it is possible that Sry delivered to the adrenal
medulla could have a corticosterone effect. Testosterone
most likely is an important factor promoting the BP rise
since our previous studies have shown that the SHR Y
chromosome produces an earlier rise in plasma testoster-
one compared to WKY males or SHR males with the WKY
Y chromosome [25]. However, we have not yet made the
direct connection between Sry and a rise in plasma testo-
sterone. Sry could have an influence in hypothalamic and
pituitary release of gonadotropins. This is an area for
future study. A piece of evidence that would suggest that
adrenal testosterone was not effected by adrenal medul-
lary injection of Sry is that in castrated WKY males we do
not detect any plasma testosterone even up to 10 weeks
after castration which is enough time for adrenal compen-
sation to take place [26]. Still it is possible that stringent
stimulation of the medulla could release cortical testoster-
one. Indeed, a provocative area of research is the crosstalk
between the adrenal cortex and medulla. A decrease in Th
in chromaffin cells can decrease adrenal cortical function
and conversely, an elevation in plasma catecholamines
can elevate plasma aldosterone and glucocorticoids [27].
Elevated Th and/or catecholamine levels are established
physiological characteristics of many hypertensive animal
models and human studies [28-31]. We have shown that
the Y chromosome from a SHR male when backcrossed to
a normotensive WKY female increased SNS indices [4]
and maintained an increase in BP of about 20 mmHg even
after 11 generations of backcrossing sons to WKY females
(SHR/y) [3]. We also showed that in SHR/y compared to
WKY, renal and heart NE turnover is higher, although the
NE organ content did not change [5]. In fact, the kidney
norepinephrine turnover rate in the SHR/y males was the
same as in SHR males suggesting that the catecholamine
pathway, at least in the kidney, is significantly influenced
by the Y chromosome [5].
Tyrosine hydroxylase activity (measured as L-DOPA formed per minute per mg tissue, fm/min/mg) in adrenal gland 3 weeks  after plasmid delivery (means, +/-s.e.m., * p <.05) Figure 2
Tyrosine hydroxylase activity (measured as L-DOPA formed per minute per mg tissue, fm/min/mg) in adrenal gland 3 weeks 
after plasmid delivery (means, +/-s.e.m., * p <.05).
0
10000
20000
30000
40000
50000
Vector
Control
Sry
*
T Ty yr ro os si in ne e
H Hy yd dr ro ox xy yl la as se e
A Ac ct ti iv vi it ty yBMC Cardiovascular Disorders 2007, 7:6 http://www.biomedcentral.com/1471-2261/7/6
Page 6 of 9
(page number not for citation purposes)
Our results showed that although Th and plasma NE were
elevated after Sry delivery, total adrenal NE content was
not elevated. One explanation for this could be that the
elevated NE release into the plasma may have depleted the
NE vesicle storage content. Multiple and complex mecha-
nisms contribute to Th activity and NE synthesis during
SNS activation. Short term mechanisms include feedback
inhibition and enzyme phosphorylation. Long term
mechanisms include changes in Th synthesis [32]. There
appears to be an uncoupling of the tissue NE content, the
activity of Th and the release of NE. Two storage pools of
NE exist in both the SNS nerve terminals and in the adre-
nal medulla: a small readily releasable pool of newly syn-
thesized NE and a large reserve pool in long term storage
[33]. For example, studies in rats show a 35% reduction in
Th activity at all ages studied (5, 12, 22 weeks) while
plasma NE was 3–4× higher in SHR compared to WKY rats
[34]. Therefore, NE storage, cytoplasmic pools and
plasma levels need not be in a linear relationship. Also,
plasma E did not increase like NE did after Sry administra-
tion. An explanation for this may be that the Sry transcript
is working on the enzyme, Th, and not on the enzyme that
produces E, PNMT. Since both end products exist in the
adrenal medulla there is not necessarily a 1/1 relationship
with NE/E.
Our results support the notion that SHR Sry increases
adrenal Th, leading to increased plasma NE and increased
peripheral vasoconstriction resulting in increased BP in a
WKY normotensive animal. Indeed, BP increased 30
mmHg after 3 weeks and adrenal Th activity increased
49% and plasma NE increased 57%. Further support for
the Th-BP connection is provided by Kumai's study show-
ing that antisense Th decreased both Th and BP in SHR
[31]. Also Kumai et al. suggest that androgens contribute
to the development and maintenance of hypertension in
Plasma catecholamines 3 weeks after plasmid delivery (means +/-s.e.m., * = p < .05) Figure 3
Plasma catecholamines 3 weeks after plasmid delivery (means +/-s.e.m., * = p < .05).
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Adrenal gland morphology is unchanged by the electroporation protocol Figure 4
Adrenal gland morphology is unchanged by the electroporation protocol. A panel-40×, B panel-100×, of representative animals 
that had nothing done-(left panels, control), had Sry delivered by electroporation (middle panels, Sry/electro) or empty vector 
delivered (right panels). The lighter color purple in the middle of the tissue is the medulla. The holes or cracks in the medulla 
are not defects but tears in the tissue from processing. Gene or empty vector delivery did not disrupt tissue morphology.
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SHR via sustained enhancement of Th synthesis in the
adrenal medulla, leading to increased epinephrine and
norepinephrine levels [19]. Further mechanistic studies
are needed to determine if Sry induced increase in Th is
associated with enhanced adrenal release of NE, altered
reuptake and other target organs, such as the adrenal cor-
tex.
Conclusion
In conclusion, we were the first group to show a Y chro-
mosome BP effect and our current findings are the first to
support SHR Sry as a candidate gene on the Y chromo-
some. Typical effects on BP attributed to other candidate
genes are small compared to the 30 mmHg effect we find
after SHR Sry delivery to WKY adrenal gland. The electro-
poration results demonstrate the potential for Sry to have
a hypertensive effect. We have suggested a mechanism
operating through the catecholamine pathway and
increased sympathetic nervous system activity which is
supported by our previous research. However, since Sry is
expressed in several different tissues that could influence
blood pressure, such as, the brain, heart and kidney, there
may be more than one mechanism and even secondary
effects of Sry on blood pressure especially through neu-
roendocrine pathways. Although this is the first Y chro-
mosome locus to have hypertensive potential
demonstrated, this result is not sufficient to conclude that
Sry is either solely or directly responsible for the hyperten-
sive effect of the SHR Y chromosome. The key to the
hypertensive effect of the SHR Y chromosome is that it
was discovered in a comparison to the normotensive WKY
Y chromosome. Further studies are needed to examine
expression and sequence differences between the SHR and
WKY Sry loci to conclude that Sry is the hypertensive locus
on the SHR Y chromosome.
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